According to a recent Growth Plus Reports study, the global non-opioid pain treatment market is estimated to hit US$ 79.46 billion by 2031, with a revenue CAGR of 8.30%. The study examines the important strategies, drivers, opportunities, competition, shifting market dynamics, market size, data and forecasts, and important investment regions.
Key Takeaways:
- The increasing prevalence of cancer, arthritis, and other diseases that lead to chronic pain conditions will drive market revenue growth.
- Increasing awareness of the benefits of non-opioid pain treatment will drive demand for non-opioid pain treatment.
- North America dominates the global non-opioid pain treatment market.
Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/nonopioid-pain-treatment-market/8455
Non-Opioid Pain Treatment Market Scope
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 38.77 billion |
|
Revenue forecast in 2031 |
US$ 79.46 billion |
|
Growth Rate |
CAGR of 8.3% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Drug Class, Pain Type, Route of Administration, Distribution Channel, and Region. |
| Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
The growth in the prevalence of chronic diseases will drive the revenue growth of the non-opioid pain treatment market. Furthermore, increasing spending on R&D and clinical trials and shifts in the regulatory environment is expected to boost the market revenue growth rate. Apart from this, the rapidly increasing prevalence of cancer, arthritis, and others that result in chronic pain conditions such as migraine, osteoarthritis, lower back pain, and localized musculoskeletal pain, along with advances in medical technology, the introduction of new drug formulations, devices, and therapies, and increased awareness of the benefits of non-opioid pain treatment are expected to support the market’s revenue growth.
Market Segmentation
Growth Plus Reports has analyzed the global non-opioid pain treatment market from five perspectives: Drug Class, Pain Type, Route of Administration, Distribution Channel, and Region.
Drug Class Segmentation: Based on the drug class, the global non-opioid pain treatment market is segmented into NSAIDs, acetaminophen, local anesthetics, and others. The NASIDs segment dominates the market with the largest revenue share because the NSAIDs are less expensive than other non-opioid pain treatment choices, come in various forms such as pills, capsules, lotions, gels, and patches, are not addictive, and have no abuse potential.
Pain Type Segmentation: Based on the pain type, the global non-opioid pain treatment market is segmented into chronic pain, post-operative pain, cancer pain, and others. The chronic pain segment dominates the market because of the growing prevalence of chronic pain, such as neuropathic pain and pain associated with inflammatory disorders, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and others, and the increased demand for non-opioid analgesic drugs.
Route of Administration Segmentation: Based on the route of administration, the global non-opioid pain treatment market is segmented into oral, injectable, topical, and other. The oral segment dominates the market because of the ease of administration, systemic effects, and advantages in managing non-opioid pain.
Distribution Channel Segmentation: Based on the distribution channel, the global non-opioid pain treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market because of the hospital pharmacies offer patients a broader range of pharmaceuticals, including biologics, that may not be available in other settings, can help make sure patients get the best therapy possible and can work closely with other healthcare professionals to provide patients with non-opioid pain therapy.
Regional Growth Dynamics
Based on the region, the global non-opioid pain treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the global non-opioid pain treatment market with the largest revenue share. The presence of key market players, an increased number of patients receiving non-opioid pain treatment, a high disposable income, improved healthcare infrastructure, and increased investment in developing highly sophisticated medication in this region are responsible for North America’s significant revenue share in the global market.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/non-opioid-pain-treatment-market/8455
Competitive Landscape
The key players in the global non-opioid pain treatment market are:
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- GSK plc.
- Pfizer Inc.
- Perrigo Company Plc.
- LNK International Inc.
- Cipla Inc.
- Johnson & Johnson Services Inc.
- Pacira Pharmaceuticals Inc.
- Pierrel
The market for non-opioid pain treatment is moderately competitive, with several multinational companies. To enhance their market position, major competitors engage in technological advancements, R&D, and mergers and acquisitions.
Recent developments:
- The US FDA granted Stride Pharma’s ibuprofen suspension ANDA competitive generic treatment (CGT) exclusivity for 180 days in June 2022. This ibuprofen suspension treats various pain conditions, such as tooth pain, muscle discomfort, arthritis, and headaches.
- Hisamitsu America celebrated Salonpas Day in May 2022 with a free patch offer from a doctor-recommended OTC pain relief patch brand.
- NEXGEL, Inc., a supplier of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced the launch of its MEDAGEL Bug Bite Relief Patch in February 2022. These soothing hydrogel patches, developed in the United States, provide immediate relief to inflamed skin caused by insect bites.
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8455
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Infusion Pump Market by Type (Volumetric Pumps, Syringe Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Implantable Pumps, and Others), by Application (Diabetes, Oncology, Pain Management, and Others), and by End User (Hospitals & Clinics, Ambulatory Care, Home Care, and Others) – Global Outlook & Forecast 2022-2030
Immunology Market by Drug Class (Monoclonal antibody (mAb), Polyclonal antibody(pAb), Fusion Protein, Immunosuppressants and Others), by Disease Indication (Rheumatoid Arthritis, Psoriatic, Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), by Distribution Channel (Hospital, Retail and Online Pharmacies) Global Outlook & Forecast Period 2022-2030
Bioelectronics Market by Type (Bioelectronic Devices, Bioelectronic Medicine), by Product (Electrochemical Biosensors, Piezoelectric Biosensors), by Application (Implantable Devices, Artificial Organs, Prosthetics, Biochips), By End User (Healthcare, Food & beverage, Environmental)– Global Outlook & Forecast 2022-2030
IV Flush Syringe Market by Type (Saline IV Flush Syringe and Heparin IV Flush Syringe), by Application (Cardiac Diseases, Rheumatoid Arthritis, Diabetes, Cancer, and Others), by End User (Hospitals, Ambulatory Surgical Centers, Clinics, and Others) – Global Outlook & Forecast 2022-2030
Cloud-based Solutions for Drug Discovery Market by Service Type (IaaS, PaaS, SaaS), End User (Pharmaceuticals, Biotechnology, Contract Research Organizations, Academia and Research Institutes) – Global Outlook & Forecast 2022-2030
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
Contact:
Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle – 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/